LYTIX — Lytix Biopharma AS Income Statement
0.000.00%
- NOK452.17m
- NOK402.11m
- NOK3.99m
Annual income statement for Lytix Biopharma AS, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
R2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | NAS | NAS | NAS | NAS | NAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.31 | 0.003 | 19.3 | 11 | 3.99 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 34.1 | 42.4 | 67.3 | 76.7 | 101 |
Operating Profit | -33.8 | -42.4 | -48 | -65.7 | -96.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -33.2 | -42.1 | -48.1 | -56.1 | -87.9 |
Net Income After Taxes | -33.2 | -42.1 | -48.1 | -56.1 | -87.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -33.2 | -42.1 | -48.1 | -56.1 | -87.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -33.2 | -42.1 | -48.1 | -56.1 | -87.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.845 | -1.07 | -1.43 | -1.39 | -2.16 |
Dividends per Share |